Share Email Print

Proceedings Paper

Reproducibility of an imaging based prostate cancer prognostic assay
Author(s): Faisal M. Khan; Douglas Powell; Valentina Bayer-Zubek; Rui Soares; Allison Mott; Gerardo Fernandez; Ricardo Mesa-Tejada; Michael J. Donovan
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

The Prostate Px prognostic assay offered by Aureon Biosciences is designed to predict progression post primary treatment for prostate cancer patients based on their diagnostic biopsy specimen. The assay is driven by the automated image analysis of biological specimens. Three different histological sections are analyzed for morphometric as well as immunofluorescence protein expression properties within areas of tumor digitally masked by expert pathologists. The assay was developed on a multi-institution cohort of up to 9 images from each of 1027 patients. The variation in histological sections, staining, pathologist tumor masking and the region of image acquisition all have the potential to significantly impact imaging features and consequently the reproducibility of the assay's results for the same patient. This study analyzed the reproducibility of the assay in 50 patients who were re-processed within 3 months in a blinded fashion as de-novo patients. The key assay results reported were in agreement in 94% of the cases. The two independent endpoints of risk classification reproduced results in 90% and 92% of the predictions. This work presents one of the first assessments of the reproducibility of a commercial assay's results given the inherent variations in images and quantitative imaging characteristics in a commercial setting.

Paper Details

Date Published: 3 March 2011
PDF: 6 pages
Proc. SPIE 7966, Medical Imaging 2011: Image Perception, Observer Performance, and Technology Assessment, 79661O (3 March 2011); doi: 10.1117/12.878241
Show Author Affiliations
Faisal M. Khan, Aureon Biosciences (United States)
Douglas Powell, Aureon Biosciences (United States)
Valentina Bayer-Zubek, Aureon Biosciences (United States)
Rui Soares, Aureon Biosciences (United States)
Allison Mott, Aureon Biosciences (United States)
Gerardo Fernandez, Aureon Biosciences (United States)
Ricardo Mesa-Tejada, Aureon Biosciences (United States)
Michael J. Donovan, Aureon Biosciences (United States)

Published in SPIE Proceedings Vol. 7966:
Medical Imaging 2011: Image Perception, Observer Performance, and Technology Assessment
David J. Manning; Craig K. Abbey, Editor(s)

© SPIE. Terms of Use
Back to Top